Drugs / LABTHERA-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05587283 | Nov 2022 → Apr 2023 | bacterial vaginosis | AtoGen Co. Ltd | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LABTHERA-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05587283 ↗ |
| Modality | Other / unclassified | “The study drug for this trial, LABTHERA-001, has been derived from the bacteria Lactobacillus plantarum ATG-K2.” NCT05587283 ↗ |
| Route | Other | “administered intravaginally once a day for 7 consecutive days” NCT05587283 ↗ |